Relmada Therapeutics, Inc. (RLMD) financial statements and ratios from SEC XBRL: revenue $1.40M (TTM), net margin -4110.7%, revenue growth -60.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.40M |
| Net Margin | -4110.7% |
| Revenue Growth (YoY) | -60.5% |
| EPS Growth (YoY) | -45.3% |
| Price / Book | 2.23 |
| Price / Sales | 247.77 |
| Altman Z-Score | 27.72 (safe) |
| Sector P/E (Healthcare) | 21.7 |
RLMD overview · RLMD earnings · RLMD KPIs · RLMD investor relations · RLMD ownership · RLMD peers · RLMD filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.